MiNK Share Price

MiNK Share Price

NASDAQ: INKT | Micro Cap | Healthcare
$7.80
+$7.80 (--%) Last updated on 21 Nov, 2026 | 01:54 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • Similar Stocks
  • FAQs

MiNK Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
$8.67 - $16.87
Volume
N/A
Average Traded
N/A

MiNK Share Price Chart

Line chart of the MiNK price trend over the selected period. The price rose overall, ranging from 7.80 to 7.80, ending at 7.80.
$0.00$0.00
L
Show Current Price
H

MiNK Stock Fundamentals & Key Indicators

Market Cap
$33.33M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.15
Revenue (TTM)
$0.00
Return On Equity (TTM)
67.84%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
1.92%

MiNK Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.20
Net Profit-$2.60-$2.74-$3.13-$2.55
Net Profit MarginN/AN/AN/A-1275.00%
Income ChangeN/A-5.38%-14.23%18.53%

MiNK Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$27.99-$22.46-$10.78-$12.49
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A19.76%52.00%-15.86%

MiNK Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets0.390.730.951.07
Current Assets13.854.993.620.4
Total Assets14.245.724.5521.47
Non Current Liabilities15.4418.3511.219.19
Current Liabilities13.036.9611.412.68
Total Liabilities28.4725.3122.6121.87
Shareholders' Equity-14.23-19.59-18.06-0.4

MiNK Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-5.93-9.56-15.76-18.87
Investing0.00.0-0.07-0.25
Financing14.7210.82-0.41-0.16

Corporate Actions

Split
Ex-date: 28 Jan 2025

About MiNK

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

MiNK Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$11.27
$7.80
-25.88%
Oct 2026
$12.83
$10.53
-16.43%
Sep 2026
$11.12
$12.60
+15.60%
Aug 2026
$11.52
$10.90
+4.21%
Jul 2026
$11.26
$10.46
-10.21%
Jun 2026
$12.27
$11.65
-4.51%
May 2026
$11.90
$12.20
+1.16%
Apr 2026
$10.29
$12.06
+10.64%
Mar 2026
$10.32
$10.90
-5.63%
Feb 2026
$11.70
$11.55
-9.77%
Jan 2026
$12.80
$12.80
+8.84%
Dec 2025
$11.21
$11.76
+7.06%

MiNK Share Price FAQs